IRIS
Caffo, Orazio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.114
EU - Europa 1.339
AS - Asia 1.208
Continente sconosciuto - Info sul continente non disponibili 339
SA - Sud America 180
AF - Africa 33
OC - Oceania 6
Totale 6.219
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.933
IT - Italia 699
SG - Singapore 429
CN - Cina 210
VN - Vietnam 189
DE - Germania 137
BR - Brasile 131
CA - Canada 112
RU - Federazione Russa 99
FI - Finlandia 95
BD - Bangladesh 90
HK - Hong Kong 83
GB - Regno Unito 64
KR - Corea 64
SE - Svezia 50
FR - Francia 45
IN - India 32
ID - Indonesia 23
LV - Lettonia 23
NL - Olanda 23
AR - Argentina 16
MX - Messico 15
IE - Irlanda 14
IQ - Iraq 14
PL - Polonia 14
AT - Austria 12
LT - Lituania 12
UA - Ucraina 12
JP - Giappone 10
SA - Arabia Saudita 10
ZA - Sudafrica 10
CR - Costa Rica 9
PH - Filippine 9
TR - Turchia 9
PR - Porto Rico 8
CO - Colombia 7
EC - Ecuador 7
EE - Estonia 7
ES - Italia 7
JM - Giamaica 7
VE - Venezuela 7
GT - Guatemala 6
HN - Honduras 6
CZ - Repubblica Ceca 5
IL - Israele 5
JO - Giordania 5
PK - Pakistan 5
AU - Australia 4
NP - Nepal 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BB - Barbados 3
CL - Cile 3
DK - Danimarca 3
EG - Egitto 3
KE - Kenya 3
MA - Marocco 3
MK - Macedonia 3
MY - Malesia 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BG - Bulgaria 2
DZ - Algeria 2
GD - Grenada 2
HU - Ungheria 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PY - Paraguay 2
QA - Qatar 2
SC - Seychelles 2
TH - Thailandia 2
UZ - Uzbekistan 2
AO - Angola 1
AZ - Azerbaigian 1
BE - Belgio 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
LB - Libano 1
LS - Lesotho 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
Totale 5.877
Salva come PNG Salva come JPEG
Città #
Ashburn 373
Singapore 304
San Jose 281
Council Bluffs 279
Trento 215
Santa Clara 112
Phoenix 104
Munich 103
Columbus 100
Milan 77
Hong Kong 76
Los Angeles 75
Helsinki 74
Dallas 68
Seoul 62
New York 59
Ho Chi Minh City 55
Rome 52
Fairfield 41
Chicago 40
Hanoi 37
Chandler 36
Moscow 31
Houston 30
Beijing 29
North Bergen 28
Riga 23
Riverside 23
Lauterbourg 21
The Dalles 21
Toronto 21
Verona 20
Jacksonville 19
Wilmington 18
Atlanta 17
Da Nang 17
Seattle 17
Montreal 16
Orem 16
Brooklyn 15
Ogden 15
Princeton 15
Buffalo 13
St Louis 13
Jakarta 12
Philadelphia 12
Secaucus 12
Cambridge 11
Cincinnati 11
Hefei 11
Miano 11
Nuremberg 11
São Paulo 11
Warsaw 11
Boardman 10
Naples 10
Shenzhen 10
Vilnius 10
Woodbridge 10
Chennai 9
Dublin 9
Florence 9
Mattarello 9
Queens 9
Salt Lake City 9
San Mateo 9
Tampa 9
Tokyo 9
Ann Arbor 8
Denver 8
Detroit 8
London 8
Mesa 8
Agrolândia 7
Bologna 7
Cleveland 7
Frankfurt am Main 7
Lappeenranta 7
Las Vegas 7
Levico Terme 7
Manchester 7
Vienna 7
Baghdad 6
Bari 6
Charlotte 6
Figino 6
Jyväskylä 6
Louisville 6
Memphis 6
Miami 6
Modena 6
Paris 6
Redondo Beach 6
San Francisco 6
San José 6
Shanghai 6
Vicenza 6
Waterbury 6
Abbeville 5
Amman 5
Totale 3.514
Salva come PNG Salva come JPEG
Nome #
A model-based framework to identify optimal administration protocols for immunotherapies in castration-resistance prostate cancer 273
TRPM8 levels determine tumor vulnerability to channel agonists. 207
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 194
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer 189
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? 173
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation 157
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations 156
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment 152
Integrating extracellular vesicle and circulating cell-free DNA analysis on a single plasma aliquot improves the detection of HER2 positivity in breast cancer patients 151
Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? 148
Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma 139
1730P Electronic medical record (EMR)-assisted phone follow-up (PFU) for breast cancer survivors (CS) during COVID-19 pandemic: An Italian single institution experience 128
Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti PD1/PDL1 therapy 124
Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience 124
Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study 123
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis 102
Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature 85
Tissue microarrays in oncology. 85
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer 84
Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma 76
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives 76
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 71
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis 62
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study 62
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials 61
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study 55
Prostate Cancer Diagnosis and Treatment in Elderly Patients: A Cross-Sectional Survey Exploring Practice Patterns and Preferences of Uro-Oncologists in Northeast Italy 55
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study 55
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis 53
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 51
Radioligand Therapies (RLTs) and Healthcare System Readiness: From the Experience in GEP-NET, a Retrospective Analysis on DRG and Mobility to Improve the Accessibility to the Future RLT in Italy 50
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 49
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) 49
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study 48
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? 48
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC 48
Association of G8 screening tool with prognosis and survival in patients with non-small cell lung cancer: A retrospective analysis from a single institution 47
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 47
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 47
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma 46
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study 46
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line 46
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 46
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 45
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide 45
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology 44
Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO) 43
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab 43
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021 43
Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases 43
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study 42
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 41
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study 41
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study) 41
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 41
A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer 40
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 40
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study 40
Darolutamide Maintenance in Patients With Metastatic Castration- Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 39
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 39
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 38
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 38
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 37
The Expanding Role of Next-generation Imaging in Prostate Cancer Management: A Cross-sectional Survey Exploring the Clinical Practice of Uro-oncologists in North-Eastern Italy; On Behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 36
Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology 36
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 36
Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU) 36
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 35
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 34
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network 33
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 32
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer 31
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone 30
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 28
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. 26
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 26
Learning from organisational changes in the management of breast cancer patients during the COVID-19 pandemic: Preparing for a second wave at a breast unit in northern Italy 26
Prognostic Value of p21WAF1 and p53 Expression in Breast Carcinoma: An Immunohistochemical Study in 261 Patients with Long-Term Follow-Up 26
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis. 26
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review 25
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer 25
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. 24
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. 24
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer 24
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study 23
Modified 3-week schedule of gemcitabine plus cisplatin for non-small cell lung cancer treatment 23
Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document 23
Use of the ONCO-TreC electronic diary compared with a standard paper diary to improve adherence to oral cancer therapy in patients with solid and haematological tumours: protocol for a randomised controlled trial 23
2-weekly docetaxel: issues for clinical practice 22
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non small cell lung cancer patients: Results from a multicenter Italian observational study. 22
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. 22
Prostate cancer: Screening and early detection 22
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 21
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 21
Association among metabolic syndrome, inflammation, and survival in prostate cancer 21
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. 21
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study 21
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial 20
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials 20
Cardiovascular toxicities of systemic treatments of prostate cancer 20
Totale 5.875
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202286 0 0 0 0 12 0 13 25 6 2 9 19
2022/202380 10 13 0 11 5 11 1 3 7 7 8 4
2023/202482 4 2 4 2 3 8 4 10 5 13 9 18
2024/2025814 13 11 43 108 49 88 86 58 94 104 41 119
2025/20262.705 104 47 141 204 137 87 237 74 724 515 142 293
2026/20272.314 212 350 732 1.008 12 0 0 0 0 0 0 0
Totale 6.219